Document is current
Any future updates will be listed below
-
Authors
Yeh, Tian-Shin
Curhan, Gary C.
Yawn, Barbara P.
Willett, Walter C.
Curhan, Sharon G.
-
Funding
Funding for this research was provided by:
National Institutes of Health grants
GlaxoSmithKline Biologicals SA
- License Information
-
More Information
Article History
Received: 22 January 2024
Accepted: 20 June 2024
First Online: 14 August 2024
Declarations
:
: The Institutional Review Boards of Brigham and Women’s Hospital and Harvard T.H. Chan School of Public Health approved the study protocol. Written informed consent were provided by all participants.
: Not applicable.
: SGC received an investigator‐initiated grant from GlaxoSmithKline Biologicals SA to examine the long‐term outcomes potentially associated with herpes zoster. GCC is an employee of OM1, receives support from an investigator‐initiated grant from GlaxoSmithKline Biologicals SA to examine the long‐term outcomes potentially associated with herpes zoster, and receives royalties from UpToDate for being an author and Section Editor. BY reports consulting with GlaxoSmithKline related to herpes zoster epidemiology and receipt of an investigator‐initiated grant related to herpes zoster and chronic obstructive pulmonary disease. GSK was provided with the opportunity to review a preliminary version of this manuscript for factual accuracy, but the authors are solely responsible for the final content and interpretation. TSY and WCW have no disclosures to report.
